期刊文献+

老年进展期胃肠道肿瘤术后腹腔化疗的临床疗效观察 被引量:3

Effect of postoperative intraperitoneal chemotherapy on advanced gastrointestina l carcinoma of senile patients
原文传递
导出
摘要 目的 探讨老年进展期胃肠道肿瘤术后腹腔化疗的临床疗效。方法 对 1992年 1月至 1997年 10月 178例 60岁以上行根治性手术后的老年进展期胃肠道肿瘤术后行腹腔化疗的病例进行回顾性分析。并将之与同期行常规静脉化疗的 12 4例进行分析比较。结果  178例腹腔化疗病人中 165例完成 6个疗程的全部化疗 ,完成率为 92 .7%。 12 4例静脉化疗病人中只有 85例完成全部的 6个疗程的化疗 ,完成率为 68.5%。 2年生存率(60 6% )、3年生存率 (55 8% )、5年生存率 (51 5% )高于静脉化疗组 (45 9%、41 1%、3 7 6% ) (P <0 0 5)。结论 老年进展期胃肠道肿瘤术后行腹腔化疗 ,药物的毒副反应小 ,病人耐受性好 ,化疗后腹腔转移率 ,肝转移率和血清肿瘤标记物水平明显低于静脉化疗组 ,术后 Objective To evaluate the effect of postoperative intraperi toneal chemotherapy on advanced gastrointestinal carcinoma of senile patients. Method s From January 1992 to October 1997, 178 senile patients (>60 years old) with advanced gastrointestinal carcinoma were treated with intraperitoneal chemothera py after radical operation in our hospital. At the same time, we compared them with intravenous chemotherapy.Results One hundred and sixty five ca ses(92.7%) i n the intraperitoneal chemotherapy group received all the 6 phases of chemothera py, but only 85 cases(68.5%) in intravenous chemotherapy group completed all t he 6 phases of chemotherapy. The 2 year survival rate (60.6%), 3 year survival r ate (55.8%) and 5 year survival rate (51.5%) in the intraperitoneal group were m uch higher than those in intravenous chemotherapy patients (45.9%, 41.1%, 37.6%, respectively)(P<0.05).Conclusion For senile patients with advanced gastro intestinal carcinoma, treatment with intraperitoneal chemotherapy after radical operation has less side effect and good toleration. Compared with intravenous ch emotherapy, it has advantages of lower metastasis rate, lower hepatic met astasis rate, lower level of CEA and CA19 9 and higher 5 year survival rate.
出处 《中国实用外科杂志》 CSCD 北大核心 2003年第12期725-727,共3页 Chinese Journal of Practical Surgery
关键词 老年进展期 胃肠道肿瘤 术后 腹腔化疗 疗效观察 腹腔种植 肝转移 Gastrointestinal carcinoma Intraperitoneal chemotherapy Perit oneal metastasis Hepatic metastasis
  • 相关文献

参考文献12

  • 1[1]Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg, 2001,25(8): 985-990
  • 2[2]Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer, 2001,92(1):71-76
  • 3[3]Janunger KG, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol, 2001,40(2-3): 309-326
  • 4[4]Ragnhammar P, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol, 2001,40(2-3): 282-308
  • 5[5]Daly JM. Intraperitoneal chemotherapy: biologic implications for clinical outcome. Ann Surg, 2000,231(4):457-459
  • 6[6]Ilson DH. Adjuvant therapy for noncolorectal cancers. Curr Opin Oncol, 2001,13(4): 287-290
  • 7[7]Jansen M, Buchin P, Dreuw B,et al. Prognostic factors for development of peritoneal carcinosis in stomach carcinoma. Chirurg, 2001,72(5):561-565
  • 8[8]Elias D, Antoun S, Goharin A, et al. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig, 2000,1(5): 431-439
  • 9[9]Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs delayed management. Dis Colon Rectum, 2000,43(10): 1341-1346
  • 10[10]Valentini V, Mantini G, Turriziani A, et al. Research trends in the treatment of colorectal cancer. Rays, 2000,25(3): 393-395

同被引文献21

  • 1陈军,尹浩然,林言箴.早期和延期腹腔内化疗对结肠癌细胞腹腔种植的影响[J].中国肿瘤临床,1997,24(3):210-213. 被引量:22
  • 2Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted anti-angiogenic gene therapy utilizing an angiostatin complemetary DNA. Cancer Res 1998;58:3362-3369.
  • 3Griscelli F, Li H, Cheong C, Opolon P, Bennaceur-Griscelli A, Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA 2000;97:6698-6703.
  • 4Ragnhammar P, Hafstrom L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282-308.
  • 5Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 2001;47:269-276.
  • 6Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001;25:985-990.
  • 7Scoff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000;19:97-107.
  • 8Plank MJ, Sleeman BD. A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. Math Med Biol 2003;20:135-181.
  • 9Kirsch M, Santarius T, Black PM, Schackert G. Therapeutic anti-angiogenesis for malignant brain tumors. Oncologie 2001;24:423-430.
  • 10Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with intergrin alpha(V)beta3 in endothelial cells. J Biol Chem 2001;276:39562-39568.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部